Research and development company BioCision has announced it is forming an independent company, MedCision which will focus on the automation of pre-clinical and clinical processes.
The newly formed company will initially focus on the commercialisation of the award-winning ThawSTAR cell thawing platform.
BioCision CEO Rolf O. Ehrhardt said: “The formation of MedCision is driven by a critical need in the market, innovative, standardization technologies and solutions for translational, clinical and point-of-care settings.
“MedCision will be a leader in developing and commercializing innovative instruments for crucial processes in the post-manufacturing cell and gene therapy space.
MedCision is created as a stand-alone company with its own management team who will provide the foundation for long-term value generation in the clinical tools sector.
Ehrhardt also stated: “The name of the company, MedCision, creates a clear connection to our BioCision roots but also conveys an evolution from those roots as our technology will focus on automating point-of-care clinical processes.”
Cell thawing refers to the final step a cellular product undergoes before patient administration. It is one of the most important parts of the post manufacturing process.
Therapeutic efficiency can be maintained by rapid, uniform, non-fluid based thawing. ThawSTAR’s automated cell thawing platform facilitates proper clinical handling and thawing in different volumes and storage formats.
Additionally, the platform automatically incorporates temperature monitoring and data connectivity, both are mandatory requisites to ensure proper sample tracking and patient safety.
The ThawSTAR platform is now used extensively into cell therapy research and development as a part of clinical trials.
The company intends to incorporate new features in ThawSTAR platform with additional models in the next one year.
MedCision will be led by former members of the BioCision senior management team. The company’s corporate office will be located in San Rafael, California.
Rolf Ehrhardt will serve as the president and CEO of the company while Ron DiNocco will be the CFO and VP of corporate development.
Eric Kunkel will be the SVP of research and development and Sam Kent is designated as SVP of global sales and business development.